Explore the Global PD-L1 Biomarker Testing Market — analysis of key trends, regional growth, top players, and a 10-year forecast from 2026 to 2036.

Future Market Insights

PD-L1 Biomarker Testing Market

Key Insight

PD-L1 biomarker testing sales will expand through 2036, with PD-L1 biomarker testing at 50.4% within the product type segment in 2026. The market was valued at USD 777.20 million in 2025, is projected to reach USD 1830.69 million by 2036 and is forecast to record an 8.1% CAGR between 2026 and 2036.

June 05, 2026

Anurag Sharma

537 Pages

Cite this Report

PD-L1 Biomarker Testing Market

https://www.futuremarketinsights.com/reports/pd-l1-biomarker-testing-market

License

Buy Now

Summary ToC Infographics Companies

Key Players

Abbott Laboratories
Abcam plc
Agilent Technologies
Bio-Rad Laboratories
Bristol-Myers Squibb
F. Hoffmann-La Roche Ag
Genentech Inc
HalioDx
Intas Pharmaceuticals Ltd
Leica Biosystems
Merck KGaA
NeoGenomics Laboratories
Shuwen Biotech Co. Ltd
Thermo Fisher Scientific Inc.

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

PD-L1 Biomarker Testing Market

Key Players

Similar Industry Reports